Although response rates cannot be determined and publication bias is likely present, responses to BRAF(/MEK) inhibition clearly occur, e.g., in contrast to BRAF-mutated colon cancer [88], and should be considered for patients with BRAF-mutated metastatic conjunctival melanoma. This evidence concerns the gene BRAF and malignant colon neoplasm.